Overview

• Inspire posted Q2 revenue of $217.1 million, up 11% year-over-year, while reporting a net loss of $0.12 per share and adjusted EPS of $0.45 that topped estimates.
• The company trimmed its 2025 sales forecast to $900 million–$910 million and cut its EPS outlook to $0.40–$0.50 from prior guidance of $2.20–$2.30.
• Management attributed the outlook reduction to slower-than-expected U.S. commercial launch of the Inspire V device, citing delays in center onboarding and SleepSync implementation.
• Executives flagged growing uptake of GLP-1 receptor agonists—such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—as a potential volume headwind for sleep apnea devices.
• Shares plunged roughly 32% in premarket trading, and analysts at KeyBanc, JPMorgan and others downgraded the stock with lower price targets.